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Abstract 
Myeloid malignancies are hematological disorders encompassing chronic 
myeloid neoplasms to acute leukemias. In recent years, insight from 
genome-wide discovery studies has improved our understanding and ability 
to predict prognosis and treatment outcome. Despite these advances, there 
remains considerable clinical heterogeneity within current classifica tion 
systems as these diseases often present with diverse and overlapping 
pathological features. At the same time, there has been limited success in 
translating these findings into effective therapeutics to improve overall 
survival. Increasingly, i t is recognized that these complex and dynamic 
molecular changes converge into a small number of biological pathways. 
Therefore, a pathway-driven approach identifying commonly perturbed 
processes could yield greater success in developing broadly applicable 
therapeutics. One promising candidate is the homologous recombination 
(HR) pathway responsible for repairing double-stranded breaks, since most 
myeloid neoplasms are characterized by gross chromosomal instability. To 
objectively assess HR repair in fresh mononuclear cells from myeloid 
malignancy patients, we developed an ex vivo , short-term assay that 
determines HR repair based on nuclear RAD51 foci induction after DNA 
damage. Using this technique, we observed HR defects in 9 of 21 myeloid 
malignancy samples. Since there is little evidence for mutational alterations 
in HR genes, we screened HR gene promoters and observed BRCA1  
promoter methylation in a significant subpopulation (22/96 samples)  that 
iii 
strongly associates with disrupted HR repair . To our knowledge, this is the 
first report linking BRCA1 methylation to HR defects in pat ient samples. 
Next, we validated the patient samples findings by silencing BRCA1  
expression in AML cells that recapitulated the HR defects. We treated AML 
cells with poly(ADP-ribose) polymerase (PARP) inhibitors and observed 
increased sensitivity with BRCA1 repression, providing a mechanistic 
justification for previous studies highlighting toxicities with PARP 
inhibitors in myeloid malignancies. The high prevalence of BRCA1  
silencing led us to consider additional roles in driving myeloid disease, as it 
is known to repress microRNA-155 (miR-155) that is frequently elevated in 
myeloid malignancies.  By correlating gene expression in the patient 
samples, we found an inverse correlation between BRCA1 and miR-155 
levels. miR-155 is frequently elevated in myeloid malignancies and its 
targets include key regulators of inflammation (SHIP1) and myeloid 
differentiation (PU.1). Our results here show that BRCA1 loss due to 
promoter methylation not only contributes to HR defects, but also 
contributes to disease progression via miR-155 upregulation.  
 
Advisor:  James G. Herman, M.D. 
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Chapter 1: Introduction 
Heterogeneity of Myeloid Neoplasms Impacts Clinical Management 
Myeloid neoplasms are clonal hematological disorders arising from malignant 
myeloid progenitor stem cells that present with diverse and overlapping 
clinicopathological features. In 2008, the World Health Organization (WHO) categorized 
myeloid malignancies into five major groups based on morphologic, genetic and clinical 
features: (1) acute myeloid leukemia (AML) and related precursor neoplasms; (2) 
myelodysplastic syndromes (MDS); (3) myeloproliferative neoplasms (MPN); (4) 
overlap MDS/MPN; and (5) myeloid neoplasms associated with eosinophilia and 
abnormalities of growth factor receptors.
1
 However, significant clinical heterogeneity 
remains and it is acknowledged that myeloid disorders represent closely linked entities 
along a continuum, and chronic MPNs, MDS and MDS/MPN have varied propensities of 
transformation to acute leukemias.
2
 The importance of defining molecular lesions driving 
myeloid malignancies that can lead to novel therapies is underlined by the fact that the 
majority of these conditions affect individuals above 60 years, creating significant 
challenges with current treatments such as intensive chemotherapy and bone marrow 
transplantation.
3,4
 Even with high-dose induction therapy, most patients have significant 
disease mortality with shorter remissions and a dismal 3-year survival of 15%.
5,6
 Despite 
promising successes, it is well accepted that most therapies are incapable of completely 
eradicating the malignant clone and current treatment is limited to supportive care 





To better define the molecular lesions driving myeloid malignancies, genome-
wide discovery studies have revealed a wide spectrum of biologically significant somatic 
alterations that has provided insights into the pathogenesis of myeloid diseases.
9-11
 The 
identification of the BCR-ABL fusion gene in chronic myelogenous leukemia (CML) 
samples led to the development of ATP-competitive inhibitors targeting to the catalytic 
activity of the ABL kinase, and treatment with these inhibitors results in impressive 
clinical outcomes that allowed patients to have normal life expectancies.
12-15
 The use of 
all-trans retinoic acid (ATRA) to convert acute promyelocytic leukemia (APL) into a 
disease with long-term remissions can be attributed to the characterization of distinct 




However, there remain significant challenges in our understanding of the 
biological relevance of the over 500 disease alleles discovered by whole-genome 
approaches.
9,10
 Development of cost-effective assays capable of detecting the wide 
spectrum of somatic alterations to deliver clinically actionable information will also face 
considerable obstacles. While somatic mutations in the Janus kinase 2 (JAK2), 
thrombopoietin receptor (MPL) and Calreticulin (CALR) genes are useful in diagnosing 
BCR-ABL negative MPNs, these alterations are present in all MPN subtypes and do not 
account for the differences in prognosis among polycythemia vera (PV), essential 
thrombocythemia (ET) and primary myelofibrosis (PMF).
17,18
 As we continue to improve 
our understanding of mutational profiles, a function-based classification of cancer-
associated changes would allow researchers to further decipher the process of malignant 
transformation and progression. 
3 
Designing Novel Therapeutics to Target Shared Pathway Deficiencies 
One solution to understand the complex genetic landscape is to characterize 
disrupted pathways in lieu of individual genomic lesions, given that recurrent mutations 
impact a restricted number of biological pathways such as RNA splicing, inflammation, 
epigenome regulation and DNA damage repair.
9
 With regards to MPNs, mutations in 
JAK2, MPL and CALR share similar transcriptional profiles in activating the JAK/STAT 
pathway, leading to the development of inhibitors targeting JAK signaling.
7,19
 Treatment 
with JAK inhibitors results in a significant reduction in splenomegaly and substantive 
symptomatic relief.
8
 Likewise, mutations in DNA methylation modifiers DNMT3A and 
TET2 found in a wide range of myeloid neoplasms have driven development of therapies 
that revert the epigenome to a normal state, exemplified by the FDA approval of 
azacitidine, a DNA methyltransferase (DNMT) inhibitor, for the treatment of MDS.
20
 
Azacitidine and decitabine, its deoxy derivative, are cytidine analogs that incorporate into 
DNA and bind irreversibly to DNMTs in order to inhibit methylation.
21
 Clinical trials 
with these drugs produce complete cytogenetic remissions and improved survival 
compared to traditional agents such as cytarabine that are observed even across the 
diverse manifestations of MDS.
22
 These encouraging developments lend weight to the 
approach of targeting novel disease-relevant pathways to reverse disease progression and 




Targeting Defects in Homologous Recombination Repair 
It is widely accepted that most cancers exhibit genetic instabilities in the form of 
unbalanced translocations, gains and losses of large sections of chromosomes.
23
 The 
interest in studying cytogenetic aberrations in myeloid diseases can be traced back to the 
discovery of the BCR-ABL translocation in CML, and subsequent studies have since 
reported chromosome abnormalities that increase in frequency with disease 
progression.
24-26
 Interestingly, many recurrent cytogenetic aberrations known to impact 
disease biology have been reported across diverse clonal myeloid diseases (MPNs, 
MDS/MPNs, sAMLs).
27,28
 In a significant proportion of AML and MDS, chromosomal 
instability has been attributed to the aberrant repair of double-strand DNA breaks 
(DSBs).
26
 DSBs arise with increased frequency in tumor cells from reactive oxidative 
stress generated by oncogenes, and can also result from external insults such as 
chemotherapy.
29
 If these lesions are not resolved in a timely fashion, they can be 





In order to maintain genomic integrity, the main DSB repair mechanisms are the 
non-homologous end joining (NHEJ) or homologous recombination (HR) pathways.
31
 
Upon induction of DSBs, a coordinated response is initiated beginning with the binding 
of ataxia telangiectasia mutated (ATM), ATM-related (ATR) and DNA-dependent 
protein kinases that phosphorylate histone H2AX variant near damage sites that in turn 
recruits downstream repair complexes.
32
 NHEJ is the preferred mechanism of DSB repair 
in G1 phase and is initiated when Ku70 and Ku80 form heterodimers that bind the free 
5 
ends at sites of damage. After further processing, the DNA ends are then ligated by DNA 
ligase IV-XRCC4.
33
 This process is known to generate errors in the form of gain or loss 
of nucleotides <20bp that contribute to genomic instability.
34
 In contrast, HR relies on 
homologous sequences on a sister chromatid during S phase for error-free repair.
35
After 
end resection by the MRE11/RAD50/NBS1 complex, RAD51 monomers bind to the 
single-stranded DNA ends to initiate homology search, strand invasion and DNA 
synthesis. The ends are then ligated before resolving the Holliday junctions.
30
 Given the 
deleterious effects of DSB lesions, genetic alterations in components of the HR pathway 
have been implicated in a variety of malignancies.
31,36
 Inherited conditions due to 
mutations in ATM, NBS, DNA ligase IV have increased predisposition to cancers 
including leukemias.
31,37,38
 Germ-line defects in BRCA1 and BRCA2 are found in the 
familial breast cancers that have a two-fold increase in gross chromosomal changes 
compared to sporadic cancers.
39,40
 In addition, Fanconi anemia and Bloom’s syndrome 
patients exhibiting pronounced HR defects have elevated risk of developing 
hematological malignancies.
41
 Mechanistically, embryonic lethality in mouse knockout 
models for HR components is often preceded by gross chromosomal rearrangements.
31,42
 
Consequently, the ability to characterize this phenotype has important implications not 
only in improving our understanding of disease pathobiology, but to allow the rational 
design of therapies targeting HR defects in tumor cells. 
 
Increasingly, the goal of anticancer agents is moving from high-dose, non-specific 
cytotoxic agents to individualized and highly selective therapy specific to neoplastic 
cells. In this regard, the concept of synthetic lethality has generated great interest by 
6 
exploiting cancer-specific defects to increase the therapeutic index between cancer and 
normal cells, making it possible to design treatments against previously undruggable 
targets while minimizing side effects. Base excision repair (BER) is an appealing target 
since disruption of this pathway leads to the accumulation of single-stranded breaks and 
subsequent stalled replication forks.
43-45
 While these stalled forks are repaired in normal 
cells with intact HR, these lesions persist in HR defective cancer cells that result in acute 
cell death.
43-45
 Poly(ADP-ribose) polymerase 1 (PARP1) localizes to DNA nicks via its 
N-terminal double zinc finger DNA-binding domains and catalyzes the covalent 
attachment of ADP-ribose groups using nicotinamide adenine dinucleotide (NAD+) as a 
substrate. 
46
 This process of PARylation alters the local chromatin environment to recruit 
other BER components for efficient DNA repair. PARP1 is also associated with 
nucleotide excision repair and the repair of stalled replication forks.
47
 Given the plethora 
of repair processes for PARP1, increased genetic instability and hypersensitivity to DNA 
damaging agents and radiation have been observed in PARP1-/- null mice. 
48
 On the other 
hand, PARP1 overexpression has been implicated in resistance to chemotherapy or 
radiotherapy.
49
 Given the above observations, it is probable that PARP1 inhibition in HR 
defective cells will have enhanced toxicity since the resulting DSBs cannot be repaired 
appropriately. In 2005, two groups demonstrated increased susceptibility to PARP1 
inhibition of BRCA1- and BRCA2-deficient systems compared to cells with normal 
BRCA functions.
43,50
 These results have since accelerated the development of PARP 
inhibitors for treating multiple solid and hematologic malignancies. In December 2014, 
the first PARP inhibitor (olaparib) was approved for heavily pre-treated advanced ovarian 
cancers with germ-line BRCA mutations after showing durable objective responses, 
7 
further signifying the immense clinical significance of this concept. Since most patients 
with myeloid malignancies are advanced in age and cannot tolerate intensive 
chemotherapy, such synthetic lethal treatments offer great potential.  
 
Given the complex network of proteins involved in HR, the function of this 
pathway can be compromised by alterations in one of more genes that are not limited to 
BRCA1 and BRCA2. Indeed, subsequent studies have reported that defects in RAD51, 
MRN, ATM, and ATR, also sensitize cancer cells to PARP1 inhibition.
51,52
 Large-scale 
loss-of-function screens also revealed genes involved in other process that mediated 
toxicity to PARP inhibition such as DDB1, XAB2 in nucleotide excision repair, and 
PTEN, a negative regulator of PI3K.
53,54
 Aside from mutations, epigenetic silencing of 
BRCA1 has also been shown to increase sensitivity to PARP inhibition in cells and 
xenografts.
55
 In chronic myelogenous leukemia (CML), the BCR-ABL fusion protein was 
shown to down-regulate BRCA1 on a post-transcriptional level that disrupts proficient 
DNA repair after ionizing radiation.
56
 Tumor-associated hypoxia can also potentiate the 
efficacy of PARP inhibitors since it is known to repress expression of HR genes to 
attenuate the DNA-damage response.
57,58
 Consequently, the range of diseases amenable 
to PARP inhibitors must be expanded beyond the current model of BRCA mutated breast 
and ovarian cancers. To identify these tumor types and realize the full potential of this 
synthetic lethal approach, assays based on novel, reliable biomarkers are critical in order 
to identify HR defects in patient tissue biopsies. 
  
8 
Functional Assays for Homologous Recombination Repair 
 With immense interest in identifying cancers with HR defects, multiple studies 
have presented methods using assays for gene expression, DNA methylation status and 
comparative genome hybridization.
59-61
 Other groups have examined HR repair by 
measuring persistence of phosphorylated histone variant H2AX foci that forms at 
DSBs.
62
 These platforms have variable degrees of predictive power but are not direct 
measures of HR repair. Initial assays for direct assessment of HR involve induction of 
DSBs using I-SceI enzyme in cells stably expressing GFP reporter plasmids, however it is 
not a feasible approach in primary samples given the challenges with transfection and ex 
vivo culture.
63
 Since RAD51 plays a central role in HR by catalyzing strand invasion into 
the homologous strand, RAD51 foci formation following DNA damage offers a 
physiologically relevant readout of HR function.
64
 Consequently, lack of RAD51 foci 





Hematological malignancies offer readily accessible transformed cells for ex vivo 
evaluation of HR repair, and several studies have exploited this fact to show defects in a 
small number of MDS and MDS/AML primary samples.
34,67,68
 However, these 
procedures require extended ex vivo (24h) treatment of primary myeloid samples with 
PARP inhibitors that not only introduces significant stress to malignant cells, but also are 
subject to confounding factors such as drug uptake and metabolism. Consequently, 
further improvements are needed to generate robust results and minimize sample loss 
during processing.  
9 
 
Ionizing radiation is an alternative approach that rapidly introduces DSBs to 
monitor HR repair.
69
 After γ-radiation exposure with caesium-137, cells are allowed to 
resolve DSBs for 2-6hrs, before fixing and staining for distinct γH2AX and RAD51 
nuclear foci as markers of DNA damage and HR repair respectively. Measurements by 
immunofluorescence indicate a rapid induction (<30min) in γH2AX foci that decreases as 
DSBs are repaired. Concurrently, RAD51 foci peak at 6h post-radiation before 
decreasing to baseline levels.
69
 This technique allows significantly shortening of ex vivo 
treatment, and has been validated as a reliable marker of PARP inhibitor sensitivity in 
primary breast and ovarian cancer cultures.
65,70-72
 Given the evidence suggestive of HR 
defects in myeloid malignancies, a direct measure of HR activity in this disease would be 
informative. 
 
Epigenetic Changes in Myeloid Malignancies on Homologous Recombination 
To identify key driver mutations amongst the over 400,000 gene mutations 
recorded in the Catalogue of Somatic Mutations in Cancer (COSMIC) database, 
Vogelstein et al. proposed a criteria based on mutation patterns and reported a total of 
294,881 mutations in 125 genes that confer a growth advantage to the malignant clone.
73
 
Intriguingly, nearly half of these genes are involved in direct regulation of DNA 
methylation and histone modification, highlighting the central role of epigenetic 
dysregulation in tumorigenesis. Epigenetic regulation plays a role in establishing tissue-
specific cellular identities, and refers to heritable gene expression changes not due to 
gene sequence changes.
74,75
 Cancer cells frequently exhibit epigenome alterations 
10 
including genome-wide losses of DNA methylation with localized increases at CpG 
islands in promoter regions, as well as chromatin structure changes that regulate 
nucleosome packaging.
75,76
 Collectively, these changes have been proposed as key 




As stated above, the epigenome can be regulated by modifications to the histones 
and DNA bases in the genome. These changes affect the configuration of nucleosomes, 
which are the basic units of chromatin that each consists of DNA wrapped around a core 
comprising two copies of the H2A, H2B, H3 and H4 variants.
78
 In turn, the chromatin 
structure around the transcription start site is a critical determinant of the transcription 
state of the corresponding gene.  
 
For actively transcribed genes, nucleosomes are widely spaced with a 
nucleosome-free region at the transcription start site to facilitate access to components of 
the gene transcription machinery. On the other hand, nucleosomes are arranged in a 
compact fashion and regularly spaced for transcriptionally silenced genes.
75-77
 Also, key 
amino acid residues on histone tails that protrude from nucleosomes can be modified by 
the addition/removal of methyl or acetyl groups that alters electrostatic charges or acts as 
protein binding domains. 
75-77,79
 Since the predominant acetylation occurs at lysine 
residues, acetylation alters the charge of the histone tail from positive to neutral, thereby 
reducing the affinity of histones to the negatively charged phosphate backbone of DNA. 
75-77,79
 Nucleosome formation may also be enhanced by positive charges of H4 histones 
and negative charges on the surfaces of H2A histone fold domains. 
75-77,79
 Disruption of 
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HDAC function and altered expression has been shown in multiple cancers, in which 
HDACs or histone methyltransferases (HMTs) form oncogenic fusion proteins and are 
aberrantly recruited to gene promoters.
80
 For example, the t(8;21) translocation in AML 
generates the AML1-ETO fusion protein that recruits HDACs to repress AML1 target 
genes and block myeloid differentiation.
80
 Likewise, in acute promyelocytic leukemia 
(APL), the PML-RARα fusion results in binding of HDACs and DNMTs to silence 
RARα target genes.
81
 Histone modifiers can also cause gene up-regulation, as observed 
with fusion proteins involving MLL, a H3K4 methyltransferase, through induction of 
H3K4me3 and H3K79me2.
82
 Understandably, there has been interest in developing 
HDAC inhibitors that have shown anticancer effects including cell death, cell cycle 




In addition to histone modifications, the epigenome can be altered by DNMTs 
that attach a methyl group from S-adenosyl-methionine (SAM) onto the 5-carbon 
position of cytosine base to form methyl-cytosine. This tends to occur predominantly at 
CpG dinucleotides, of which over 70% are methylated in the human genome in normal 
cells. In contrast, “CpG islands” that are in close proximity to promoter regions of over 
half of the genes in the human genome are highly concentrated in unmethylated CpGs.
84
 
These regions of at least 200bp have an observed to expected CpG ratio greater than 
60%and a GC percentage greater than 50%.
84
 Loss of DNA methylation at repetitive 
regions of the genome may result in the expression of inserted viral genes and repeat 
elements, or disrupt the functional stability of pericentromeric regions.
75
 On the other 
hand, methylation of CpG islands results in the aberrant silencing of tumor suppressor 
12 
genes in cancer cells and can represent the second hit of the Knudson two-hit hypothesis 
to inactivate gene expression similar to gene mutations. Increasingly, it is acknowledged 
that the number of genes inactivated by epigenetic silencing is at least as prevalent as 
those attributed to mutations in cancers.
75,85,86
 The biologic effects of promoter 
methylation are also similar to exome mutations, as seen in breast cancers where genetic 
and epigenetic changes in BRCA1 produce similar gene expression microarray 
profiles.
75,85,87
 Promoter hypermethylation of MLH1 also generates microsatellite 
instability in colon tumors analogous to mutational inactivation. As mentioned above, 
DNMTs can be aberrantly recruited to CpG islands near gene promoters to inactivate 
tumor suppressors by further binding of other transcription repressor proteins. In contrast 
to gene mutations, DNA methylation can be reversed by demethylating agents such as 
azacitidine to re-express silenced genes. Furthermore, DNA hypermethylation changes 
are known to occur early in cancer progression, hence there is the potential for cancer 
prevention by inhibiting or reversing these alterations.
77,88
. This strategy has shown 
promising results in MDS patients where reactivation of the cyclin-dependent kinase 
inhibitor p15 was observed with azacitidine treatment.
89
 Because epigenetic changes are 
dynamic, aberrant promoter methylation and gene silencing can reappear once the 





The clinical implications of studying DNA methylation can be extended to its 
utility as a molecular biomarker for cancers. When collecting clinical material from 
patients, delays in processing are common that might compromise sample quality. Hence 
13 
promoter methylation determination can be more suitable for clinical applications given 
the stability of DNA relative to RNA and protein. In addition, detection of a single region 
near gene promoters for DNA methylation offers a simple approach compared to 
mutations in tumor suppressor genes that tend to be located throughout the gene body.
73,75
 
Identification of a positive methylation signal on a background of unmethylated normal 
samples also improves the ease of detection especially when coupled with sensitive 
assays such as polymerase chain reaction (PCR) methods.
75,86,91
 The methylation specific 
PCR (MSP) technique has been successfully used to identify abnormal promoter 
methylation in a variety of samples (tissue, serum, sputum, urine).
75
 Since DNA 
methylation changes are early events in cancer progression, it is possible to identify 
cancer from sputum using MSP analysis before clinical detection of lung tumors in 
smokers.
92
 For myeloid malignancies such as MPN, MDS and mixed MDS/MPN, we 
hypothesize that studying these early epigenetic changes can shed light on pathways that 
can be targeted early to halt leukemic transformation. 
 
Objectives 
We have previously performed single nucleotide polymorphism array (SNP-A) 
analysis in MPNs and found chromosome losses encompassing HR genes that also 
correlated with defective induction of RAD51 foci.
93
 In the same study, we also 
demonstrated decreased colony formation in samples with defective HR when treated 
with PARP inhibitors. Collectively, these results not only suggest that defective HR 
repair occurs early in myeloid malignancies, but also can be a useful biomarker for 
PARPi therapy to prevent disease progression. At the same time, given the widespread 
14 
observation of chromosomal instability, we hypothesize that this pathway defect can be 
extended to other myeloid malignancies (MDS, MDS/MPN, AML). To do so, we would 
need to develop a short-term ex vivo assay capable of assessing HR repair in primary 
patient samples. Our next goal is to investigate the molecular mechanisms that underlie 
the pronounced DNA repair defects in myeloid malignancies. Since sequencing analysis 
of HR repair genes in AML and MDS patients with impaired DSB repair revealed a 
limited number of HR gene mutations that do not fully account for the prevalence of 
defective HR, we investigated if epigenetic silencing via promoter methylation can 
account for this deficiency.
67,88,94
 Finally, we are interested in understanding alternative 
mechanisms in which the molecular aberration drives myeloid disease progression. 
  
15 
Chapter 2: BRCA1 Promoter Methylation is Associated with 
Homologous Recombination Repair Defects and Elevated miR-155 in 
Myeloid Malignancies  
Introduction 
Myeloid malignancies are a heterogeneous collection of clonal hematological disorders 
that span precursor neoplasms such as chronic myeloproliferative neoplasms (MPN), 
myelodysplastic syndromes (MDS) and overlap mixed MDS/MPNs, to de novo acute 
leukemias (AML) and secondary AMLs (sAML).
1
 The majority of pre-leukemic 
conditions (MPN, MDS, mixed MDS/MPN) affect individuals above 60 years, making 
potential curative treatments such as intensive chemotherapy and bone marrow 
transplantation difficult.
4
 With the exception of BCR-ABL chronic myelogenous 
leukemia (CML), many of these disorders continue to be distinguished by morphological 
features and quantitative differences in myeloid components, reflecting the lack of 
molecular insight into disease-specific pathogenesis. This highlights the urgent need to 
elucidate novel disease pathways targetable with currently available drugs, without which 
patients continue to be at significant risk of bone marrow failure and leukemic 
transformation.
95
 Given the common morphologic, cytogenetic and genetic 
abnormalities,
27,28
 we hypothesized that the same pathways are disrupted across the 
diverse spectrum of myeloid neoplasms. Consequently, therapies designed to target these 
shared functional defects would be more efficacious for this diverse group of diseases. 
 
However, direct analysis of the high fidelity, error-free HR pathway in myeloid 
malignancies is lacking compared to breast and ovarian cancers.
43
 This dearth of 
16 
knowledge has therapeutic importance, given the increased interest in HR repair with the 
approval of olaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi), for BRCA1-
mutated ovarian cancer.
96
 Since PARPi is exquisitely toxic to HR defective malignant 
cells and spares normal tissues, a comprehensive study of HR repair and associated 
molecular aberrations in myeloid malignancies could determine if patients are potentially 
sensitive to this therapy.
43,44
 To address this gap, we developed a short-term ex vivo 
radiation-based HR assay for primary cells from myeloid neoplasms and discovered 
common functional defects in HR repair. Next, we investigated epigenetic silencing of 
HR genes to elucidate the underlying molecular events and observed frequent BRCA1 
promoter methylation that was strongly associated with HR defects. With the observation 
of increased PARPi sensitivity in BRCA1-repressed cells, we reasoned that a substantial 
proportion of myeloid neoplasm patients might be amenable to this form of synthetic 
lethal therapy, using BRCA1 promoter methylation as an epigenetic biomarker for 
responders. The increased prevalence of BRCA1 silencing relative to other HR genes 
also suggests additional roles of BRCA1 loss in driving myeloid disease progression and 
here we present evidence that BRCA1 loss up-regulates the oncomiR miR-155 that targets 
multiple proteins essential for myeloid differentiation and inflammation.
97-101
 In 
conclusion, this is the first study demonstrating that epigenetic silencing of BRCA1 not 
only associates with HR defects in primary samples, but also increases miR-155 








Materials and Methods  
 
Patient Samples 
Peripheral blood or bone marrow aspirates were collected and analyzed under IRB 
approved protocols at the Johns Hopkins Hospital.  All patients provided informed 
consent in accordance with the Declaration of Helsinki. Patient characteristics are 
provided in Table 1. Mononuclear leukocytes were isolated by density centrifugation 
with Ficoll-Paque Plus (GE Healthcare, Piscataway, NJ, USA). The ZR-Duet DNA/RNA 
MiniPrep kit (Zymo Research, Orange, CA, USA) was used to obtain genomic DNA 





HR repair assay 
The HR status of primary mononuclear cells was evaluated as described by Patel et al. 
with modifications.
104
 After density centrifugation, at least five million cells were re-
suspended in RPMI media with 10% (v/v) fetal bovine serum (FBS), radiated with 10Gy 
using a Gammacell 1000A 
137
Cs source (Atomic Energy of Canada) at a rate of 
2.3Gy/min and placed in 37
0
C, 5% CO2 in humidified atmosphere for six hours. The cells 
were pelleted, washed with PBS and fixed with 2% formaldehyde. 250,000 cells were 
cytospun onto poly-lysine coated slides, permeabilized with 0.25% (v/v) Triton X-100 in 
PBS and incubated in blocking buffer for 1h (PBS with 1% (v/v) glycerol, 0.1% (w/v) 
fish skin gelatin, 0.1% (w/v) BSA, 5% (v/v) goat serum and 0.4% (w/v) sodium azide). 
Slides were incubated overnight at 4
0
C with RAD51 rabbit polyclonal (ActiveMotif) and 
19 
phosphor-Ser139 H2AX mouse monoclonal (Millipore) antibodies diluted 1:500 in 
blocking buffer. Cells were then incubated for 1h with secondary Alexa Fluor 488 goat 
anti-mouse and Alexa Fluor 555 goat anti-rabbit antibodies (Invitrogen) diluted 1:1000. 
Slides were washed, counterstained with 1μg/ml Hoechst 33258 for 5min and then 
mounted with Prolong Gold antifade reagent (Life Technologies).  
 
Confocal images were obtained with a Nikon C1si confocal laser-scanning microscope 
with a 100X.1.4 N.A. oil-immersion objective at excitation wavelengths of 408, 488, and 
561nm. Maximum projection images were generated from optical sections of 0.5μm 
increments and processed in ImageJ using the PZFociEZ macro. All image analysis 
parameters were kept constant for each pair of mock and irradiated sample. As with 
previous studies, cells positive for RAD51 and phospho-H2AX foci are defined as having 
≥5 foci per nucleus.
44,71
 HR competent cells had greater than two-fold increase in 
percentage of RAD51-foci positive cells.
65,70
 More than 100 cells from at least three 
fields were analyzed for each sample. All irradiated samples exhibited greater than two-
fold increase in the percentage of phospho-H2AX foci positive cells. 
 
SNP array analysis  
Chromosomal alterations (deletion, amplification, uniparental disomy) involving 
candidate genes in a cohort of primary myeloproliferative neoplasm cases were 
interrogated from results previously described.
103
 The list of genes in recurrently 
disrupted chromosome regions was analyzed using the gene ontology (GO) EASE 





Methylation-specific PCR (MSP), quantitative MSP (qMSP) 
Genomic DNA was bisulfite-treated with the EZ DNA Methylation Kit (Zymo Research). 
The initial MSP screen was performed as previously described.
106
 qMSP for BRCA1 
promoter methylation, normalized to beta-actin levels, was carried out using the iTaq 
SYBR Green mix and 300nM of each primer. qMSP, MSP primer sequences and 
annealing temperatures are listed in supplemental Table 1. Cycling conditions are 95
0
C 
for 5min, followed by 40 cycles of 95
0
C for 5sec and 64
0
C for 60sec. Melt curve readings 
were recorded at 0.5
0




C. The controls for unmethylated and 
methylated templates were bisulfite-treated samples from normal lymphocyte DNA and 
CpG Methylated Jurkat genomic DNA (NEB) respectively. Methylated samples are 
defined as amplicons with melting temperatures matching that of the methylated control.  
 
Quantitative real-time PCR (qRT-PCR) 
cDNA was synthesized from 1μg RNA isolated from samples processed within 6h after 
collection using the iScript Reverse Transcription Supermix (Bio-Rad). Transcript levels 
were measured in triplicate with the CFX96 Touch Real-Time PCR Detection System in 
a 15μl reaction including 1μl diluted cDNA, 250nM of each primer and 7.5μl 
SsoAdvanced SYBR Green mix (Bio-Rad).  Primer sequences are listed in Table S1. 
BRCA1 expression was quantified using the 2
-ΔΔCt
 method after normalizing to GAPDH. 
 
microRNA expression analysis 
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200ng of total RNA was reverse-transcribed using the qScript™ microRNA cDNA 
Synthesis Kit (Quanta BioSciences) and real-time quantitative analysis was performed in 
20μl reaction volume containing SsoAdvanced SYBR Green mix (Bio-Rad), 10μM 
PerfeCTa Universal PCR primer and 10μM PerfeCTa miRNA assay primer in the CFX96 
Touch Real-Time PCR Detection System according to manufacturer’s instructions. miR-




Cell culture and reagents 
OCI-AML3 were grown in RPMI media supplemented with 20% FBS, 100units/ml 
pencillin and 100μg/ml streptomycin. HEK293 cells were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) with 10% FBS. All cells were maintained at 37
0
C, 5% 
CO2 in humidified atmosphere. For HDACi treatment, cells were treated with 
suberoylanilide hydroxamic acid (SAHA) for 72h. 
 
Lentivirus generation and transduction 
HEK293 cells were transfected with BRCA1-specific or non-targeting shRNA (Sigma), 
psPAX2 packaging and pMD2.G envelope DNA. The culture medium was replaced after 
12h, and supernatant containing lentivirus was collected at 24h and 48h. Concentrated 
lentivirus stock and 8μg/ml polybrene were added to OCI-AML3 and HL-60 cells and 
spun at 2400rpm for 60min. The supernatant was discarded and the cell pellet was re-
suspended in culture media. After 48h, transduced cells were selected with 2μg/ml 
puromycin for seven days and repression confirmed by qRT-PCR. 
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Cell viability assay for PARP inhibitor sensitivity 
2500 cells were seeded in triplicate in a 96-well plate and treated with PARP inhibitor 
ABT-888 (ApexBio) at 0.01% final DMSO concentration for 72h. Cell viability was 






Identification of Alterations in HR Genes 
Inactivation of tumor suppressor genes in cancer often involves genetic alterations, loss 
of chromosome regions and abnormal promoter hypermethylation. In myeloid 
malignancies, mutations in HR genes are infrequent and have not shown a conclusive 
association with functional disruption of HR.
2,67
 Using EASE to identify biological 
pathways enriched for genomic loss, we next reexamined SNP-A results from a previous 
study of 144 MPN patients, but found no association for the homologous recombination 
pathway of statistical significance (p=0.121).
93
 Since hematological disorders display 
frequent alterations in CpG methylation,
107-110
 we explored whether epigenetic alterations 
could produce HR defects. BRCA1 CpG island methylation has been found to be 
predictive of sensitivity to PARP inhibitors in breast cancer,
111
 and another study 
demonstrated a high incidence of this epigenetic change in treatment related AML.
112
 As 
a first approach to determine which HR genes might be altered by promoter region 
methylation, we examined previously collected MPN, AML and acute lymphoid 
leukemia (ALL) samples.
102,103
. As reported in supplemental Table 2, we observed CpG 
island promoter methylation of BRCA1 (MPN: 6/66, 9.09%; AML: 2/26, 7.69%), FANC-
C (AML: 1/30, 3.33%) and FANC-L (AML: 1/30, 3.33%).  These epigenetic events were 
absent in ALL samples and normal lymphocytes, suggesting a specific association with 
myeloid malignant cells. The remaining HR genes (BRCA2, ATM, ATR, and FANC-A) 
showed no evidence of promoter CpG island methylation (supplemental Table 2). 
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Homologous Recombination is Frequently Defective in Myeloid Neoplasms 
In response to DNA DSBs, the formation of RAD51 foci at sites of damage has been well 
established as a marker of HR repair.
65,70-72
 However, previous studies of the HR pathway 
in myeloid malignancies required extended treatment (24h) with DNA damaging agents, 
which limits the investigation to a small number of transformed cases due to the stress of 
prolonged ex vivo culture.
67,68
 In addition, the influence of drug uptake and metabolism 
cannot be controlled. We have previously characterized impaired RAD51 foci induction 
in a small cohort of MPN samples that was associated with PARP inhibitor sensitivity.
93
 
Here, we expanded our study to include the pre-leukemic conditions (MDS, MPN, 
MDS/MPNs) for a more comprehensive investigation of HR defects in myeloid 
neoplasms (supplemental Table 3). To minimize the effects associated with lengthy drug 
incubations, we exposed primary cells to ionizing radiation, which has been previously 
shown to induce similar levels of DSBs to DNA damaging drugs.
104
 We also restricted 
our assessment to fresh viable samples processed within 6h after collection. We 
performed this assay in 21 patient samples (14 MDS/MPNs, 5 MPNs, 1 sAML, 1 
therapy-related MDS). For each pair of mock and radiated samples, we performed 
immunofluorescence and confocal microscopy for γH2AX and RAD51 foci as markers of 
DSB and HR respectively (Figure 1A, supplemental Figure S1).  The percentage of both 
γH2AX- and RAD51-foci positive cells (≥5 foci per cell) was determined in mock and 
radiated fractions (Figure 1B top). In order to account for differences in baseline 
characteristics, we determined the fold change after radiation (Figure 1B bottom). All 
irradiated samples demonstrated a greater than two-fold increase in percentage of 
γH2AX-foci positive cells post-radiation, confirming that irradiation generated 
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reproducible and robust DNA DSB damage.  A two-fold induction of RAD51-foci 
positive cells post-radiation was used to define functional HR.  The failure to achieve a 
two-fold induction of RAD51-positve cells has previously been demonstrated to correlate 
with PARP inhibitor sensitivity.
65,70
 Using this improved approach that reduces 
subjectivity and variation during sample and image processing, we observed diminished 
RAD51 foci induction in 9 of 21 (43%) samples, demonstrating a high prevalence of 
impaired HR in myeloid malignancies (Figure 1C).   
 
Epigenetic Silencing of BRCA1 is Associated with HR Defects 
To determine if promoter region hypermethylation of these genes functionally produced 
the HR defective phenotype, we examined 96 DNA samples from 51 unique patients and 
carried out a focused methylation analysis of BRCA1, FANC-C, FANC-L since our pilot 
study had suggested these genes could be affected by promoter region methylation 
(Figure 2). Sequential samples for some patients allowed us to monitor molecular 
changes over time. There was no promoter methylation of FANC-C and FANC-L in any 
of these patients, suggesting that epigenetic silencing of these genes is rare in myeloid 
neoplasms (data not shown), and could not account for the observed frequency of HR 
defects. We refined the methylation detection for BRCA1 to exclude amplification of 
unconverted DNA, using a real-time quantitative MSP (qMSP) assay with melt curve 
analysis to compare the melting temperature of each amplicon to that of the in vitro 
methylated positive control. With this approach, as shown in Figure 2A, we detected 
BRCA1 methylation in 22.9% (22/96) of the samples, corresponding to 12 of 51 (23.5%) 
patients. Among the patients with sequential samples for analysis, we found promoter 
26 
methylation to be unchanged over time in most patients, with persistent absence of 
methylation in 14 patients and retained methylation in four cases (10, 12, 28, 33).  There 
was loss of BRCA1 methylation in subsequent samples for two patients (19, 23), while in 
two cases (1, 17) we observed BRCA1 methylation in samples collected at later time 
points (Figure 2A). A review of the patient history revealed that patient 23 had received 
5’azacytidine, a demethylating agent, after the first sample was collected, potentially 
explaining that loss of methylation. The onset of BRCA methylation seen in patients 1 
and 17 suggests that acquiring BRCA1 methylation may be a feature of disease 
progression.  
 
To determine whether promoter methylation of BRCA1 was associated with 
transcriptional repression, we examined BRCA1 expression in 88 samples with RNA 
available. We found statistically significant lower expression in cases with BRCA1 
promoter hypermethylation compared to those samples lacking methylation (P<0.05, 
unpaired t-test) (Figure 2B). In the subset of samples with HR status, we found a 
statistically significant association between BRCA1 methylation and HR defects (P<0.05, 
Fisher’s Exact Test, Table 2). We next classified BRCA1 expression with HR and BRCA1 
promoter methylation according to HR and promoter methylation status (Figure 2C). HR 
defective samples with BRCA1 CpG island methylation exhibited significantly lower 
BRCA1 gene expression compared to HR competent cases with unmethylated BRCA1 
(P<0.05, unpaired t-test). Of note, all four BRCA1 methylated samples were defective for 
HR, suggesting that this epigenetic silencing event disrupted HR repair (Figure 2C). For 
HR defective samples that were unmethylated for BRCA1, we observed varying levels of 
27 
BRCA1 expression suggestive of dysregulation in other HR genes and the possibility of 
BRCA1 repression through alternative mechanisms (mutations, chromatin repression) as 
the cause of HR defect. We also observed in patient 17, the acquisition of 
hypermethylation of BRCA1 promoter at the later time-point was associated with 
disruption of HR repair, while the initial sample from this patient was unmethylated and 
had intact HR repair (supplemental Figure 2). Overall, promoter methylation and 
silencing of BRCA1 was strongly associated with HR defects, showing for the first time 
how this epigenetic event disrupts the HR pathway in myeloid malignancy. 
 
Repression of BRCA1 Expression Results in PARPi Sensitivity 
To determine if HR defects due to BRCA1 inactivation can be exploited by therapies that 
selectively target HR deficient cancer cells, we examined in vitro sensitivity to the PARP 
inhibitor ABT-888 (veliparib). BRCA1 inactivation has been associated with increased 
sensitivity to PARP inhibition in breast and ovarian cancer due to the synthetic lethal 
killing of HR defective cancer cells.
43
 To determine whether BRCA1 loss would create a 
similar sensitive phenotype in myeloid cells, we stably expressed two independent short 
hairpin RNAs targeting BRCA1 in the OCI-AML3 cell line that is unmethylated for 
BRCA1 promoter and was previously characterized as HR competent.
67
 This resulted in 
BRCA1 repression and impaired RAD51 foci induction, recapitulating the association 
observed in primary samples (Figure 3A, 3B). We then measured cell viability after 72h 
exposure to ABT-888 and observed a statistically significant decrease in IC50 values with 
BRCA1 knockdown (scrambled control: 16.2μM; BRCA1 sh34: 7.5μM; BRCA1 sh49: 
5.72μM) (P<0.0001, F-test), indicative of increased sensitivity to PARP inhibition 
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(Figure 3C).  These results demonstrate that loss of BRCA1 impairs HR and leads to 
increased sensitivity to PARP inhibition, pointing to a therapeutic approach for the subset 
of myeloid neoplasm patients with HR defects and BRCA1 promoter methylation as an 
epigenetic biomarker to identify potential responders to this therapy. 
 
BRCA1 Represses miR-155 Expression via HDACs  
In addition to this important role for BRCA1 in HR, we hypothesized that there may be 
additional consequences of BRCA1 inactivation in myeloid neoplastic cells that confer 
transformed cells a growth advantage.  It has been shown in breast cancer that BRCA1 
directly represses miR-155 by recruiting a repressive complex that includes histone 
deacetylase 2 (HDAC2) to the miR-155 promoter.
113
 This is of relevance in myeloid 
malignancies since previous studies have identified miR-155 as an oncomiR that is 
frequently over-expressed and promotes myeloid lineage expansion of hematopoietic 
stem cells.
98,99
 However, an association between miR-155 up-regulation and BRCA1 loss 
in myeloid malignancies has not been reported. Therefore, we examined miR-155 
expression in patient samples and found a statistically significant inverse correlation with 
BRCA1 expression (Spearman correlation coefficient r:-0.245, P<0.05) (Figure 4A), 
suggesting that BRCA1 loss was associated with increased miR-155 expression. To 
directly test whether this was caused by BRCA1 loss, we examined miR-155 expression 
following repression of BRCA1 in OCI-AML3 cells and observed a >1.5-fold increase in 
miR-155 levels (Figure 4B).  Since the mechanism proposed by which BRCA1 represses 
miR-155 involves HDAC2, we treated OCI-AML3 cells with SAHA, a pan-HDAC 
inhibitor. This resulted in a dose-dependent increase in miR-155 expression following 
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SAHA treatment, further implicating BRCA1 in repression of miR-155 as mediated via 
HDACs (Figure 4C).  
 
Loss of miR-155 repression is associated with reduction in myeloid differentiation 
genes 
As an oncogenic microRNA, multiple miR-155 targets have been proposed, including 
PU.1 and SHIP1.
97,100,114,115
 These proteins have well-established roles in myeloid 
differentiation and both have been reported to be frequently downregulated in myeloid 
malignancies.
100,101,116
 Therefore, we examined if increased miR-155 observed in BRCA1 
silenced myeloid malignancies was associated with expression of these target genes.   We 
indeed found a strong inverse correlation of both PU.1 and SHIP1 transcript levels 
(Figure 4D, 4E) with expression of miR-155 (PU.1: Spearman correlation r:-0.264, 
P<0.05; SHIP1: Spearman correlation r:-0.364, P<0.005).  This suggests a mechanism 
involving loss of BRCA1 repression leading to miR-155 up-regulation, promoting 





Myeloid malignancies often present with significant clinical heterogeneity, which 
presents a challenge for diagnosis and the identification of genetic aberrations that can be 
effectively targeted.
117
 Recently, the favorable activity of PARP inhibitors on tumors 
with HR deficiencies has generated further interest in characterizing disease systems for 
these defects. Given that myeloid malignancies are characterized by gross chromosomal 
instability, PARP inhibitors represent promising therapies for these patients given the 
synthetic lethal effect in sparing normal tissues.
67,118,119
 A detailed investigation of the 
HR repair pathway within the diverse spectrum of myeloid disease is needed. In this 
study, we investigated acute leukemia and pre-leukemic disorders (MPN, MDS, mixed 
MDS/MPN) to determine the prevalence of HR functional defects. To address the lack of 
a short-term, ex vivo HR assay for hematological samples, we have developed an ionizing 
radiation-based assay and determined HR repair function by measuring RAD51 foci 
recruitment to DSB sites. This modification has allowed us to comprehensively and 
objectively query HR competency and conclude that a high proportion (43%) of myeloid 
malignancies exhibit HR defects.  
 
Increasingly, it is acknowledged that HR repair defect can arise in sporadic cancers from 
molecular aberrations aside from mutations in BRCA1/2.
120
 To identify the molecular 
underpinning of this HR defect, we considered the various mechanisms of disrupting HR 
genes, including mutation, loss of heterozygosity and promoter methylation. Multiple 
genetic studies have described germ-line mutations in HR repair genes in hematologic 
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neoplasms (ATM, BLM, Fanconi Anemia), but these events are infrequent in sporadic 
myeloid disorders.
2,67,121
 Analysis of genomic regions lost in MPN also failed to highlight 
the HR pathway as significantly disrupted. BRCA1 promoter methylation was previously 
identified in a significant proportion of treatment related AML patients that correlated 
with complex karyotypes, but the HR pathway was not evaluated in that study.
112
 Here, 
we reported BRCA1 CpG island methylation in a significant proportion of patient 
samples. More importantly, this is the first study correlating epigenetic silencing of 
BRCA1 with HR defects in primary samples, strongly highlighting BRCA1 promoter 
methylation as a promising biomarker for HR defects and resultant sensitivity to PARP 
inhibition. In clinical research settings, we acknowledge that it may not be feasible to 
obtain clinical samples in a timely manner required to perform the HR assay and gene 
expression analyses. Hence the ability to detect stable epigenetic changes in a simple and 
sensitive manner favors promoter hypermethylation as a clinical biomarker.  
 
The HR and BRCA1 methylation assays demonstrated here could be developed into 
valuable companion tools for evaluating hematological samples in a clinical setting to 
inform decisions for incorporating PARP inhibitors. The recent approval of olaparib for 
BRCA mutated ovarian cancer based on improved progression free survival illustrates the 
clinical benefit of this agent for tumors that lack HR, a strategy that is actively pursued in 
multiple malignancies.
96,122,123
 The ABT-888 IC50 values of BRCA1-repressed cells are 
below the single-dose Cmax readings recorded in preclinical animal models, highlighting a 
therapeutic window to apply this agent for this population.
124
 Two clinical trials are 
ongoing at the Johns Hopkins Hospital (ClinicalTrials.gov Identifier: NCT01139970, 
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NCT00588991) to evaluate the effects of adding PARP inhibitor ABT-888 in 
combination with chemotherapeutic agents for hematological disorders.  
 
Despite the numerous genes involved in HR, the exclusivity and prevalence of BRCA1 
epigenetic inactivation in myeloid neoplasms suggest the potential for additional roles in 
which loss of BRCA1 drives disease progression in addition to defective DSB repair. The 
recent finding that BRCA1 represses oncogenic miR-155 provides a possible role, given 
that miR-155 is frequently up-regulated in myeloid malignancies and studies showing 
ectopic overexpression of miR-155 in mouse models results in a myeloproliferative-like 
phenotype.
97-99,113,114
 Our findings of an inverse correlation of BRCA1 and miR-155 
transcripts in patient samples, increased miR-155 levels in the BRCA1-silenced cells, and 
confirmation that this is repression mediated by HDACs are in agreement with previous 
findings in breast cancers suggesting a transcriptional repressor role for BRCA1.
113
 Given 
the prominent role of miR-155 in normal and pathogenic hematological systems, and the 
direct targeting of PU.1 and SHIP1 by this oncogenic miRNA, our result highlight a HR-
independent mechanism by which BRCA1 loss drives myeloid disease progression.  
 
In conclusion, our findings suggest that a subset of myeloid malignancies exhibit HR 
defects, which can be mediated by epigenetic silencing of BRCA1, and are therefore 
susceptible to the synthetic lethal killing effects of PARP inhibitors. Further investigation 
is warranted to determine if HR status and BRCA1 methylation can predict favorable 
outcomes with PARP inhibition in myeloid malignancies, which may usher in a novel 




Figure 1. Homologous recombination repair is impaired in myeloid neoplasms.  
(A) Representative confocal images after processing with ImageJ macro PZFociEZ to 
highlight foci (right). Robust induction of RAD51 foci was observed in HR competent 
cells (HR+), but not in cells defective for HR (HR-). Images were obtained with a Nikon 
C1si confocal laser-scanning microscope using a 100X.1.4 N.A. oil-immersion objective. 
Excitation wavelengths were 408nm (DAPI), 488nm (γH2AX), and 561nm (RAD51). 
The scale bar represents two microns. (B) Quantification of RAD51-foci positive (≥ 5 
foci) cells in samples shown in (A). HR competent cells are defined as having greater 
than 2-fold increase in percentage of RAD51 positive cells after irradiation, indicated by 
the red-dotted line. (C) Summary result of HR functional assay for primary patient 
samples shows defective HR in 9 of 21 (42.9%) samples.  
 
Figure 2. Epigenetic silencing of BRCA1 is linked to HR repair defects.  
(A) BRCA1 qMSP results. Unique patient samples are labeled numerically. Multiple 
samples from the same patient are indicated alphabetically, in chronological order. (B) 
Dot-plot of BRCA1 expression relative to normal controls (NL) classified by promoter 
methylation. The line represents the median. *, P<0.05 (unpaired t-test with Welch’s 
correction) (C) Dot-plot of BRCA1 expression according to HR repair status and 
promoter hypermethylation. HR defective, BRCA1 methylated samples exhibit lower 
BRCA1 expression compared to HR competent, BRCA1 unmethylated samples. UM: 
unmethylated, M: methylated. The line represents the median. *, P<0.05 (unpaired t-test) 
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Figure 3. Stable Repression of BRCA1 induces HR defects and increased PARP 
inhibitor ABT-888 sensitivity.  
(A) BRCA1 shRNA-mediated repression in OCI-AML3 cells confirmed by qPCR. (B) 
BRCA1-repressed cells failed to induce RAD51 foci with irradiation. Error bars represent 
SEM. (C) Increased sensitivity to PARP inhibitor ABT-888 was observed with BRCA1-
knockdown. Cell viability was accessed 72h after adding ABT-888. The data is shown 
with SD as error bars.  
 
Figure 4. BRCA1 loss relieves HDAC-mediated repression of miR-155 that results in 
decreased expression of downstream miR-155 targets implicated in myeloid disease. 
(A) BRCA1 and miR-155 expression levels were plotted for primary samples, showing an 
inverse correlation. (B) miR-155 expression is elevated in BRCA1-silenced OCI-AML3 
cells. (C) Treatment with HDAC inhibitor SAHA results in increased miR-155 
expression. Error bars in (A) and (B) represent SEM of three independent experiments. 
(D) PU.1 and (E) SHIP1 expression were plotted against that of miR-155 after log2 
transformation of the transcript levels relative to normal lymphocytes. The number of 
pairs (n), Spearman correlation coefficient (r) and P values are shown. 
 
Supplemental Figure 1.  A significant proportion of myeloid neoplasm 
samples display abnormal HR repair.  Image analysis of foci-positive 
nuclei was performed for each pair of mock and radiated sample, using 
identical image processing parameters. Cells positive for phospho-H2AX and 
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RAD51 foci are defined as having ≥5 foci per nucleus. More than 100 cells from at least 
three fields were analyzed for each sample. All irradiated samples exhibited greater than 
two-fold increase in the percentage of phospho-H2AX foci positive cells. 
 
Supplemental Figure S2. BRCA1 qMSP results of samples assayed for 
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Figure 2. Epigenetic silencing of BRCA1 is linked to HR repair defects.  
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Figure 3. Stable Repression of BRCA1 induces HR defects and increased PARP 
inhibitor ABT-888 sensitivity.  
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Figure 4. BRCA1 loss relieves HDAC-mediated repression of miR-155 that results in 
decreased expression of downstream miR-155 targets implicated in myeloid disease.  
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Supplemental Figure 1.  A significant proportion of myeloid neoplasm samples 









Table 1. Study cohort characteristics.  
 
 MDS/MPN MDS/AML MPN 
Unique Patients  32 9 16 
Samples     
gDNA (methylation)  74 12 26 
RNA (gene expression) 60 9  





Table 2. Association between BRCA1 methylation and HR defects .  
 
 HR competent HR defect   
MDS/MPN 7 12 P<0.05, Fisher’s 





Supplemental Table 1. Primer sequences for qMSP, MSP, RT -qPCR 
qMSP Primer sequence 5'-3'     Tm 
M-BRCA1 




sense GGG TGG TTA ATT TAG AGT TTC GAG AGA CG   




    
  
Actin 











    
  
MSP Primer sequence 5'-3'     Tm 
FANC-C 




UM sense TGTTGTTGTAATTTTGTTTTTGTTGGGGTTTTTG   
UM antisense AACACAACCAAAACTCTAACAAAAATAAACCCA   
M sense GACCAAAACTCTAACGAAAATAAACCCG 
 
  
M antisense TTGTTGTAATTTTGTTTTCGTCGGGGTTTTC   
  
    
  
FANC-L 















    
  
FANC-F 




UM sense TATGTTAGTATTTGGGATTTTGTTATTGTGTGTTG   
UM antisense CTAATTATACAACCACCACTCCAAAACCATACA   
M sense TATTTGGGATTTCGTTATCGTGCGTC 
 
  




    
  
BRCA2 




UM sense TGATTTTTGGGTGGTGTGTGTGTTGTG 
 
  
UM antisense CAAAAACACAACAATACCACAACAACTCCA   
M sense TTTTCGGGTGGTGCGTGTGTTGCG 
 
  




    
  
FANC-N 




UM sense GATTTTGGTTATTTTTGGTTGTTTTTTTATTTTTG   
UM antisense AACCATAAACAACCAAACAATAAAACAAAACCA   
M sense ATTTCGGTTATTTTCGGTCGTTTTTTTATTTTC   
M antisense GACCGAACAATAAAACGAAACCG   
  
    
  
ATM 
    
  





UM antisense AACAACCACAAAACACAATATACCCATACA   
M sense CGTTTGTTTCGACGGGTC 
  
  




    
  
FANC-A 




UM sense TAGGTGTTTTTTTTAGGATTAATATGGTTATGATG   
UM antisense CAAACACACACACCCATTAACTAACAACA 
 
  
M sense GGCGTTTTTTTTAGGATTAATATGGTTACGAC   
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BLOOM 




UM sense GAAGTAGTTAATTGGAATAGGTAAGTTTTTGGTG   
UM antisense CCTCACACACAAACTCCTAACAAACA   
M sense TAGTTAATCGGAATAGGTAAGTTTTCGGC   
M antisense CACGCAAACTCCTAACGAACG   
  
    
  
FANC-D2 


















    
  
FANC-E 




UM sense TTGGTTTTATGTTTAGGTTTTGTTTTTGGTTGTG   
UM antisense CTATTACAAACTCTCCTCAACATTAAAAAACCA   
M sense TTTAGGTTTCGTTTTCGGTCGC   
M antisense TCTCCTCGACGTTAAAAAACCG   
  
    
  
FANC-G 




UM sense TTTGTTTATTTTTTTTTGAGGTTGTGGTTTTTGTG   
UM antisense CAAACAAACTTAAACAAACTAAAAACCAAAATCA   
M sense GTTTATTTTTTTTCGAGGTTGTGGTTTTCGC   
M antisense AAACAAACTTAAACGAACTAAAAACCGAAATCG   
  
    
  
FANC-I 




UM sense TGTTTTTTTTTGATTGTGAGTTGGGATGTTTTTG   
UM antisense ACTTCCACCATCCAAATACCTACAAACA   
M sense TTTTTTTTCGATTGTGAGTTGGGACGTTTTC   
M antisense CCGTCCGAATACCTACGAACG   
      
FANC-J 




UM sense GGATTTGTTGGAGTGGTGATAATTTTTTGTTGTG   
UM antisense AATCCCAATACAAAATAAAAAAACAAAAACTTCA   
M sense AGTGGCGATAATTTTTCGTCGC   
M antisense CCGATACGAAATAAAAAAACGAAAACTTCG   
      
ATR 




UM sense GTTTGGTGTTGAGAAAGAAGTTTGATGTGATTTG   
UM antisense TTCTACATAAAACCCAAAAAAAACCAAAAAACCA   
M sense TGTTGAGAAAGAAGTTTGACGCGATTC   
M antisense TACATAAAACCCGAAAAAAACCGAAAAACCG   
  
    
  
RT-qPCR Primer sequence 5'-3'     Tm 









      
GAPDH 







antisense ATGGGTGGAATCATATTGGAAC     
46 
Chapter 3: Conclusion 
 
Targeting HR Defects in Myeloid Malignancies 
 The recent approval of the PARP inhibitor olaparib for  advanced 
ovarian cancers now presents a promising therapeutic option for other 
malignancies with HR defects.
122
 Hence, there is a concerted effort to  
uncover predictive biomarkers of defective  HR to better stratify patients for 
targeted therapeutics instead of the conventional cancer -type specific 
approach. However, in contrast to breast and ovarian cancers, detailed 
studies of HR repair in myeloid malignancies are wanting in part due to the 
lack of optimal HR assays designed for primary myeloid malignant samples. 
This needs to be addressed urgently as there is a significant unmet clinical 
need for effective therapies with reduced toxicities compared to current 
regimes. Given the frequent chromosomal aberrations reported for theses 
diseases, there is an suggestions that  defective HR could be a common 
mechanism for genomic alterations across multiple myeloid disorders.  
27,28
 
Hence, we set out to develop a short-term, ex vivo  assay by modifying 
existing HR assays to determine the presence and prevalence of defects in 
HR, using ionizing radiation to rapidly induce DSBs and quantifying 
RAD51 foci induction indicative of proficient HR. Given the limitations of 
previous assays because of  the variability associated with imaging analys is, 
we performed these measurements with consistent parameters between each 
pair of mock and radiated sample using an ImageJ macro . By implementing 
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these adaptations, we believe this assay can be more widely implemented in 
research settings to provide a more comprehensive and accurate 
understanding of HR repair. With this technique, we were able to assay 21 
primary samples and found frequent incidence of impaired RAD51 foci 
induction (9/21 samples, 43%). These findings are promising for 
investigators choosing to focus on targeting HR repair deficiency in this 
group of diseases. Since there are few molecular targeted agents available  
for such patients, PARP inhibitors represent another possible therapeutic 
approach to halt disease progression in MPN, MDS and MDS/MPN patients 
who are at high risk of acute leukemic transformation.
2
 Previous studies 
have alluded to the potential of incorporating PARP  inhibitors into AML 
therapy, but these were often restricted to a small number of patient samples 
that insufficiently answer the prevalence of HR defects in myeloid 
malignancies.
67,68
 To our knowledge, this is the first study looking at 
defective HR across multiple myeloid neoplasms that suggests this 
deficiency is not limited to transformed AML cases.  
 
However, we also recognize obstacles to translate this technique into 
routine clinical assays: 1) the requirement for sufficient number of viable 
cells (at least 2x10
6
), and 2) the lack of a cell cycle specific marker to 
identify dividing cells. For myeloid conditions such as MDS and MF where 
it might not be feasible to obtain sufficient patient tissue, adjustments w ill 
be needed to scale down this approach so that it may be used with a limited 
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number of cells. During the course of this work, a study was published that 
incorporated geminin staining as a marker of proliferating cells .
72
 This may 
allow normalization for cells of differing rates of cell growth. Nonetheless, 
given the ease of access to fresh viable malignant cells in most myeloid 
neoplasms compared to solid cancers, HR assays could be extremely 
informative in the context of clinical trials with PARP inhibitors.  
 
At the same time, we investigated the molecular mechanism 
underlying HR defects, focusing on epigenetic silencing of HR genes given 
the low incidence of mutations in this group of diseases.
2,67,121
 We observed 
promoter DNA methylation of BRCA1 in 23% (22/96) of the patient samples 
that is closely linked to defective HR. This result not only provides a 
mechanistic explanation for disrupted HR repair, but also offers a robust 
biomarker that makes easier the process of identifying patients who are 
potentially amenable to PARPi therapies. More importantly, these patients 
with BRCA1 promoter methylation and HR defects may not be considered 
eligible for trials involving PARP inhibitors based on the current criteria of 
BRCA mutations or clinical features that are associated with BRCA 
mutations.
47
 Our results here support the addition of DNA methylation of BRCA1 for 
patient selection, which has been shown to exhibit similar gene expression profiles as 
BRCA1 mutated cancers, to extend the presumed benefits of PARP inhibitors to a larger 
patient population.
125
 The observation of HR defective samples in our study that do not 
exhibit BRCA1 promoter methylation suggests alterations in other HR genes or alternate 
49 
forms (chromatin repression) of BRCA1 repression. Going forward, it will be informative 
to perform whole-genome analysis (sequencing, DNA methylation, SNP-A, ChIP-seq) to 
unravel these alternative mechanisms. 
 
BRCA1 Loss and miR-155 Up-regulation in Myeloid Neoplasms 
In our study, we also observed an inverse correlation between BRCA1 
and miR-155 levels in both patient samples and the BRCA1-silenced OCI-
AML3 cells. This provides critical insight into the regulation of miR -155, 
which is highly expressed in myeloid malignancies and elevated miR -155 
have been associated with inferior outcomes in AML patients.
97,100,114,115
 This 
provides an additional mechanism other than defects in HR by which BRCA1 loss 
contributes to myeloid transformation, and such loss could lead to cells that are more 
aggressive in nature. Retrospective analyses of patient DNA with clinical outcomes will 
help shed light on this finding.  
 
Acquired Resistance 
 Since PARP inhibitors may exhibit reduced major side effects by selectively 
targeting HR defective cancers, these agents are suitable for long-term treatments to 
convert lethal cancers into chronic diseases. However, it is acknowledged that tumors can 
develop resistance to PARP inhibitors over time through multiple mechanisms: 1) 
increased drug efflux or 2) restoration of HR repair by reversion of BRCA1 activity. One 
solution is to inhibit P-glycoprotein activity that is known to increase drug efflux. For 
resistant tumors with partially restored HR, a possible approach is using drug 
50 
combinations such as platinum drugs, although this would induce more severe side 





Collectively, this body of work highlights myeloid neoplasms as a 
potential disease model amenable to PARP inhibitors, with the appropriate 
functional assay or DNA methylation analysis. This approach is currently 
being evaluated in clinical trials incorporating PARP inhibitors in myeloid 
malignancies (J0783, PI: Keith Pratz, MD; J1051, PI: Ivana Gojo, MD ). 
Further studies are required to correlate clinical response to functional 
status of HR repair and DNA methylation of BRCA1.  
51 
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 Early-stage, translational research scientist in DNA repair and epigenetic biomarkers. 
 Highly collaborative researcher across clinical and bench research, cumulating in 
seven co-authored peer-reviewed publications and four manuscripts in preparation. 
 Designed and processed more than 150 samples from myeloid neoplasm patients.  
 Developed ex vivo confocal imaging assay for DNA repair in primary samples. 
 Established protocol for examining epigenetic silencing of DNA repair genes in 
patient samples. 
 Supported clinical trials evaluating poly (ADP) ribose polymerase (PARP) inhibitors 
in myeloid malignancies. 
 Oversaw marketing and research operations in Philadelphia-based biotech startup 
(Vector Biolabs, Inc). 
 
Academic and Research Experience        
2010-June 
2015 
Johns Hopkins University. School of Medicine. Pathobiology Ph.D. 
Program. 
 Conferred Margaret Lee Fellowship for outstanding Singaporean 
applicants. 
Mentor: James G. Herman, M.D.  
Thesis: Epigenetic Silencing of BRCA1 Creates Homologous 
Recombination Repair Defects and Impaired Differentiation through 
Elevated miR-155 Expression in Myeloid Neoplasms 
 Developed clinical collaboration and primary tissue processing 
protocol with the Johns Hopkins Hospital clinicians. 
 Discovered functional DNA repair defect in myeloid neoplasm that 
is attributed to epigenetic silencing of HR genes. 
 Demonstrated that DNA repair defects and epigenetic silencing 
predicts favorable response to PARP inhibitors.  
 Attended weekly clinical conferences discussing lymphoma and 
myeloid malignancy patient cases. 
Significance: Epigenetic biomarkers can be used to select for 
responders to PARP inhibitors from myeloid neoplasm patients who 
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currently lack curative therapy. This approach is currently explored in 
clinical trials at the Johns Hopkins Hospital. 
Translational Rotation: Johns Hopkins Hospital. Surgical Pathology. 
Jonathan Epstein, MD. 
 Observed surgical sample processing from gross examination to 
frozen/fixed tissue sectioning and pathologist evaluation. 
Translational Rotation: Johns Hopkins Hospital. Division of 
Hematology. Ivana Gojo, MD. 
 Shadowed hematologist interactions with elderly leukemia patients 
in managing and monitoring disease symptoms. 
 
  
Academic and Research Experience (continued)       
2009-2010  
 
Agency for Science, Technology and Research (A*STAR), 
Singapore. Institute of Medical Biology. Singapore Oncogenome 
Project. Research Officer. 
 Designed projects to examine effect of tyrosine kinase 
inhibitors in hepatocellular carcinoma cell lines. 
 Optimized assays for fluorescence-activated cell sorting of 
cancer stem cells. 
2008-2009: Agency for Science, Technology and Research (A*STAR), 
Singapore. Institute of Medical Biology. Singapore Oncogenome 
Project. Honors Year Research Student. 
Mentors: Axel Ullrich, Ph.D., Han Kiat Ho, Ph.D. 
Thesis: Klotho-beta overexpression as a novel target for 
suppressing proliferation and fibroblast growth factor receptor-4 
signaling in hepatocellular carcinoma 
 Analyzed gene expression in paired normal and tumor tissues 
from hepatocellular carcinoma patients. 
 Determined a liver tissue specific co-receptor protein in the 
FGFR pathway is upregulated in HCC samples. 
 Demonstrated increased expression of CD133 and CD44, 
markers associated with cancer stem cells, with prolonged 
treatment of FGFR4 kinase inhibitor. 
Significance: This work highlights a tissue-restricted protein in the 
FGFR pathway that can be targeted by chemotherapy to minimize 
systemic toxicities.  
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2007-2008: Agency for Science, Technology and Research (A*STAR). Institute 
of Molecular and Cell Biology. Molecular Virology and Viral 
Pathogenesis Lab, Undergraduate Research Student. 
Mentor: Ding Xiang Liu, Ph.D. 
Thesis: Identification of RIG-I caspase activation recruitment 
domain (CARD) Interacting Cellular Proteins 
 Generated mutant RIG-I deficient in IRF3 activation by 
mutagenesis PCR cloning. 
 Identified novel interacting partners to RNA sensor protein RIG-
I by conducting protein immunoprecipitation followed by mass 
spectrometry.  
Significance: Documented a novel interaction of HSP70 with RIG-I 




Graduate Student Instructor. Pathology for Graduate Students: Basic Mechanisms. 
2011 




 Isolating primary mononuclear cells from bone marrow aspirates and peripheral 
blood. 
 Developing an ex vivo radiation assay in primary leukocytes to access homologous 
recombination. 
 Optimizing immunofluorescence staining protocol to detect irradiation induced 
foci. 
 Designing methylation-specific PCR (MSP) to detect promoter methylation of 
DNA repair gene. 
 PCR-cloning based bisulfite sequencing. 
 Reverse transcriptase quantitative PCR (RT-qPCR) detection of gene and 
microRNA expression. 
 Cell culture of adherent and suspension cell lines.  
 Generating shRNA-expressing lentivirus for transduction into acute leukemic cell 
(AML) lines. 
 Plasmid cloning and bacterial transformation to generate fusion gene constructs. 
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 Real time cell viability assays to monitor drug sensitivity to drug treatment with 
gene repression. 
 Treatment with histone deacetylase inhibitors to monitor changes in gene 
expression and histone acetylation. 
 Chromatin immunoprecipitation (ChIP) qPCR for histone marks.  
 
External Poster Presentations 
American Society of Hematology Annual Meeting. 2014. 
W. Poh, A. R. Moliterno, K. W. Pratz, I. Gojo, M. A. McDevitt and J. G. Herman 
“Epigenetic Silencing of BRCA1 Is Linked to Homologous Recombination Repair 
Defects and Elevated mir-155 Expression in Myeloid Neoplasms.” 
American Association of Cancer Research Annual Meeting. 2013. 
W. Poh, R. L. Dilley, M. A. Healey, A. R. Moliterno, K. W. Pratz, M. A. McDevitt 
and J. G. Herman. "BRCA1 promoter methylation and homologous recombination 
repair status in primary chronic myeloid neoplasms."  
 
Awards and Honors 
First Place: Local Medical Product (JHU Entrepreneurship Week). 2014. 
Medical and Education Perspectives (MEP), BME EDGE, Innovation Factory. 
Headed PathoVax, based on a broadly protective Human Papillomavirus (HPV) 
vaccine, that beat over 20 teams to win the Local Medical Product category. Awarded 
$1000 cash and $5000 for commercialization. 
Student Travel Award. 2014. 
Graduate Student Association, Johns Hopkins University. 
Awarded $200 for poster presentation at the American Society of Hematology Meeting 
2014. 
AAAS/Science Program for Excellence in Science Student Fellowship. 2011. 
Awarded two-year membership in AAAS. 
Margaret Lee Fellowship. 2010. 
Department of Pathology, Johns Hopkins University 
One of three students selected from Singapore and Korea to receive funding for 
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high-resolution melt for ultrasensitive detection and analysis of rare epiallelic 
variants.” (Manuscript in preparation) 
C. K. Lee, W. Poh, M. A. Healey, E. S. Schafer, P. Brown, J. G. Herman.
 
“Pcft Is 
Silenced By DNA Methylation In Pediatric Acute Lymphoblastic Leukemia Resulting 
In Decreased Methotrexate Uptake.” (Manuscript in preparation) 
M. A. Healey, W. Poh, V. Winnepennenickx, C. Hooker, J. G. Herman. "Methylation 
of MMP11 is an independent negative prognostic marker for survival in melanoma." 
(Manuscript in preparation) 
R. L. Dilley, W. Poh, D. E. Gladstone, J. G. Herman, M. M. Showel, J. E. Karp, M. A. 
McDevitt and K. W. Pratz (2014). "Poly (ADP-ribose) polymerase inhibitor CEP-8983 
synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro." 
Leukemia Research 38(3): 411-417. 
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Herman, W. Poh, L. Pelosof, C. L. Wolfgang, B. Vogelstein, K. W. Kinzler, R. H. 
Hruban, N. Papadopoulos and L. D. Wood (2014). "Whole-exome sequencing of 
pancreatic neoplasms with acinar differentiation." The Journal of Pathology 232(4): 
428-435. 
S. N. Shah, L. Cope, W. Poh, A. Belton, S. Roy, C. C. Talbot, Jr., S. Sukumar, D. L. 
Huso and L. M. Resar (2013). "HMGA1: a master regulator of tumor progression in 
triple-negative breast cancer cells." PLoS One 8(5): e63419. 
C. M. Heaphy, K. C. Schreck, E. Raabe, X. G. Mao, P. An, Q. Chu, W. Poh, Y. Jiao, 
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Finalist, Johns Hopkins Business and Consulting Club Mini-Case Competition. 
2014. 
Johns Hopkins Business and Consulting Club (JHBCC) 
Part of two-man team selected as finalist (out of 16 teams). Given three hours to 
analyze and present profitability recommendations for Tesla.  
 
The Columbia Graduate Consulting Club 2014 Case Competition. 2014.  
The Columbia Graduate Consulting Club, Columbia University, New York 
Part of five-person team selected for finals at the Columbia University. Analyzed 
business case involving mobile payment technology and presented recommendations to 
industry consultants within four hours. 
 
3rd Annual Spring Biotech Business Case Competition. 2013.  
Johns Hopkins Business and Consulting Club (JHBCC) 
Part of three-person team analyzing case of medical device OEM exploring expansion 
into novel product categories. 
 
 
